Table 1. Incidence of deep-vein thrombosis and pulmonary thromboembolism by patient characteristics with ovarian cancer and borderline tumour.
| Characteristics | DVT | OR (95% CI) | P-value | PTE | OR (95% CI) | P-value |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| <50 | 5/23 (21.7%) | Reference | 3/23 (13.0%) | Reference | ||
| ⩾50 | 13/49 (26.5%) | 1.30 (0.40–4.21) | 0.66 | 5/49 (10.2%) | 0.76 (0.16–3.49) | 0.66 |
| BMI | ||||||
| <25 | 14/53 (26.4%) | Reference | 7/53 (13.2%) | Reference | ||
| ⩾25 | 4/19 (21.1%) | 0.74 (0.21–2.62) | 0.64 | 1/19 (5.3%) | 0.36 (0.04–3.18) | 0.34 |
| FIGO stage (1989) | ||||||
| Stage I/II | 9/38 (23.7%) | Reference | 5/38 (13.2%) | Reference | ||
| Stage III/IV | 9/34 (26.5%) | 1.16 (0.40–3.37) | 0.79 | 3/34 (8.8%) | 0.63 (0.14–2.90) | 0.56 |
| Histology | ||||||
| Serous carcinoma | 5/31 (16.1%) | Reference | 1/31 (3.2%) | Reference | ||
| CCC | 7/14 (50.0%) | 5.20 (1.26–21.5) | 0.02 | 5/14 (35.7%) | 16.7 (1.72–161) | <0.01 |
| Others | 4/15 (26.7%) | 1.89 (0.43–8.41) | 0.40 | 2/15 (13.3%) | 4.62 (0.38–55.5) | 0.51 |
| Borderline tumour | 2/12 (16.7%) | 1.04 (0.17–6.26) | 0.97 | 0/12 (0.00%) | ND | |
| Non-CCC | 11/58 (19.0%) | Reference | 3/58 (5.2%) | Reference | ||
| CCC | 7/14 (50.0%) | 4.27 (1.24–14.7) | 0.02 | 5/14 (35.7%) | 10.2 (2.07–50.2) | <0.01 |
| Massive ascites a | ||||||
| Absent | 10/54 (18.5%) | Reference | 6/54 (11.1%) | Reference | ||
| Present | 8/18 (44.4%) | 3.52 (1.11–11.2) | 0.03 | 2/18 (11.1%) | 1.00 (0.18–5.46) | 1.00 |
| Tumour size (cm) | ||||||
| <10 | 6/26 (23.1%) | Reference | 3/26 (11.5%) | Reference | ||
| ⩾10 | 12/46 (26.1%) | 1.18 (0.38–3.62) | 0.78 | 5/46 (10.9%) | 0.93 (0.20–4.27) | 0.93 |
BMI=body mass index; CCC=clear cell carcinoma; CT=computed tomography; DVT=deep-vein thrombosis; FIGO=International Federation of Gynecology and Obstetrics; ND=not done; OR=odds ratio; 95% CI=95% confidence interval; PTE=pulmonary thromboembolism.
a
Massive ascites was defined as centralisation detected by CT in this study.